Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychiatry Research and Reviews
  4. Volume 21, Issue 3
  5. Article
Volume 21, Issue 3
  • ISSN: 2666-0822
  • E-ISSN: 2666-0830

Abstract

Background

Depression, a form of mood illness, is characterized by a lack of or diminished social life, melancholy, and symptoms linked to an uplifted or depressed mood. Vincamine and Melatonin combination may prove beneficial for treating depression because vincamine and melatonin have already been reported in the treatment of dementia. Dementia is a CNS disorder which is connected to the level of neurotransmitters at the synaptic cleft, which is similar to depression that is why it might be effective in the treatment of depression.

Aim

The aim of this research is to conduct an experimental study on the antidepressant activity of Vincamine alone and along with Melatonin and comparison with standard antidepressant drugs.

Method

In this study, all animals are trained for the experiment, and then animals are divided into groups according to the treatment protocol. Animals were placed for the rest for 1 week. Vincamine and melatonin were administered to the treated groups on days 8 and 21 for the behavioral analysis using different kinds of models like elevated plus maze, forced swim test, open field test and sucrose preference test. Animals were sacrificed at day 22 for the estimation of biochemical (SOD) and neurotransmitters (Serotonin, Norepinephrine and Dopamine).

Results

After extensive investigation, it has been established that Vincamine, alone and in combination with Melatonin, is beneficial in treating depression. Positive results are obtained. The group treated with Vincamine taken per oral route (10 mg/kg), Melatonin (10 mg/kg), Vincamine + Melatonin (10 mg/kg + 10 mg/kg) and std (10 mg/kg) treatment showed significant result which are followed as for all groups (a) < 0.0001 . NC; (b) < 0.0001 . disease control; (c) < 0.05 . Std (10 mg/kg); (d) < 0.001V . M (10 mg/kg); (e) < 0.0090 . V+M (10 mg/kg+10 mg/kg). It was demonstrated by a number of behavioral (elevated plus maze, forced swim test, open field test, and sucrose preference test) and biochemical parameters (estimation of neurotransmitters such as serotonin, norepinephrine, and dopamine). Vincamine alone and in combination with Melatonin demonstrated positive results ( < 0.0001) in the evaluation of the SOD antioxidant defence system. Also, it significantly attenuated the alteration in locomotor activity, oxidative stress and neurotransmitters in rat brain.

Conclusion

It has been concluded that vincamine alone and along with melatonin is effective for the treatment of depression on the basis of behavioural and biochemical parameters. That’s why it might be useful for the future prospect.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cprr/10.2174/0126660822293380240516114111
2024-05-27
2025-04-24

  • From This Site

    /content/journals/cprr/10.2174/0126660822293380240516114111
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KaltenboeckA. HarmerC. The neuroscience of depressive disorders: A brief review of the past and some considerations about the future.Brain Neurosci. Adv.201822398212818799269
     [Google Scholar]
  2. PalazidouE. The neurobiology of depression.Br. Med. Bull.2012101112714510.1093/bmb/lds004 22334281
     [Google Scholar]
  3. KesslerR.C. BerglundP. DemlerO. JinR. MerikangasK.R. WaltersE.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication.Arch. Gen. Psychiatry200562659360210.1001/archpsyc.62.6.593 15939837
     [Google Scholar]
  4. DeepakC SandhyaM. A study on depression among geriatric in a rural population of Uttar Pradesh, India.JACM201811014
     [Google Scholar]
  5. EvansD.L. CharneyD.S. LewisL. Mood disorders in the medically ill: Scientific review and recommendations.Biol. Psychiatry200558317518910.1016/j.biopsych.2005.05.001 16084838
     [Google Scholar]
  6. RaisonC.L. MillerA.H. Depression in cancer: New developments regarding diagnosis and treatment.Biol. Psychiatry200354328329410.1016/S0006‑3223(03)00413‑X 12893104
     [Google Scholar]
  7. RivelliS. JiangW. Depression and ischemic heart disease: What have we learned from clinical trials?Curr. Opin. Cardiol.200722428629110.1097/HCO.0b013e3281ead011 17556879
     [Google Scholar]
  8. BentonT. StaabJ. EvansD.L. Medical co-morbidity in depressive disorders.Ann. Clin. Psychiatry200719428930310.1080/10401230701653542 18058286
     [Google Scholar]
  9. TalhaJ. AmanI.S. MehnazK. Antidepressant activity of methanolic extract of verbena officinalis linn. plant in mice.Asian J. Pharm. Clin. Res.201584308310
     [Google Scholar]
  10. ZhuS. ZhaoL. FanY. Interaction between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia.Psychoneuroendocrinology202011410459510.1016/j.psyneuen.2020.104595 32036201
     [Google Scholar]
  11. DepressionAvailable from: https://www.who.int/health-topics/depression
  12. SharmaSk. Medicinal Plants used in Ayurveda.New DelhiRashtriya Ayurveda Vidyapeeth, Ministry of Health and Family Welfare, Govt of India1998193
     [Google Scholar]
  13. The Wealth of India-Raw Materials.New DelhiPublication and Information Directorate, Council of Scientific and Industrial Research1985
     [Google Scholar]
  14. BeeR AhmadM VermaS. A review on exploring the potential of Vincamine alone and along with Melatonin as an effective anti-depressant agent.Curr Drug Res Rev20232023.10.2174/2589977515666230825095036
     [Google Scholar]
  15. LernerA.B. CaseJ.D. TakahashiY. LeeT.H. MoriW. Isolation of melatonin, the pineal gland factor that lightens melanocyteS1.J. Am. Chem. Soc.19588010258710.1021/ja01543a060
     [Google Scholar]
  16. AllegraM. ReiterR.J. TanD.X. GentileC. TesoriereL. LivreaM.A. The chemistry of melatonin’s interaction with reactive species.J. Pineal Res.200334111010.1034/j.1600‑079X.2003.02112.x 12485365
     [Google Scholar]
  17. MartaB. SzafrańskaK. PosmykM.M. Exogenous melatonin improves antioxidant defense in cucumber seeds (Cucumis sativus L.) germinated under chilling stress.Front Plant Sci2016757510.3389/fpls.2016.00575 27200048
     [Google Scholar]
  18. FischerT.W. KleszczyńskiK. HardkopL.H. KruseN. ZillikensD. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR‐induced depletion, and protects against the formation of DNA damage (8‐hydroxy‐2′‐deoxyguanosine) in ex vivo human skin.J. Pineal Res.201354330331210.1111/jpi.12018 23110400
     [Google Scholar]
  19. NelsonJ.C. Augmentation strategies in depression 2000.J. Clin. Psychiatry200061S21319 10714619
     [Google Scholar]
  20. De MontignyC. CournoyerG. MorissetteR. LangloisR. CailléG. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.Arch. Gen. Psychiatry198340121327133410.1001/archpsyc.1983.01790110069012 6418109
     [Google Scholar]
  21. ReynoldsC.F.III FrankE. PerelJ.M. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression.Am. J. Psychiatry1996153111418142210.1176/ajp.153.11.1418 8890674
     [Google Scholar]
  22. CoppenA. ShawD. FarrellJ. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan.Lancet19632817272798110.1016/S0140‑6736(63)91084‑5 14022907
     [Google Scholar]
  23. PareC.M.B. Potentiation of monoamine-oxidase inhibitors by tryptophan.Lancet1963282730652752810.1016/S0140‑6736(63)90271‑X 14065433
     [Google Scholar]
  24. GlassmanA.H. PlatmanS.R. Potentiation of a monoamine oxidase inhibitor by tryptophan.J. Psychiatr. Res.196972838810.1016/0022‑3956(69)90013‑2 4917709
     [Google Scholar]
  25. GutierrezA.J.L. AlinoL.I.J.J. Tryptophan and an MAOI (nialamide) in the treatment of depression. A double-blind study.Int. Pharmacopsychiat.197162929710.1159/000468258 4950287
     [Google Scholar]
  26. WhartonR.N. PerelJ.M. DaytonP.G. MalitzS. A potential clinical use for methylphenidate with tricyclic antidepressants.Am. J. Psychiatry1971127121619162510.1176/ajp.127.12.1619 4998422
     [Google Scholar]
  27. FeighnerJ.P. HerbsteinJ. DamloujiN. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.J. Clin. Psychiatry1985466206209 3997787
     [Google Scholar]
  28. FawcettJ. KravitzH.M. ZajeckaJ.M. SchaffM.R. FreishtatH.W. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression.J. Clin. Psychopharmacol.199111212713210.1097/00004714‑199104000‑00010 2056139
     [Google Scholar]
  29. NaorS. TalmonY. GuyN. Combined tricyclic antidepressants and ritalin in elderly depressives.Harefuah19921237-8251252, 307 1459498
     [Google Scholar]
  30. LinetL.S. Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine.Am. J. Psychiatry19891466803b410.1176/ajp.146.6.803b 2786343
     [Google Scholar]
  31. PrangeA.J.Jr WilsonI.C. RabonA.M. LiptonM.A. Enhancement of imipramine antidepressant activity by thyroid hormone.Am. J. Psychiatry1969126445746910.1176/ajp.126.4.457 4185164
     [Google Scholar]
  32. GoodwinF.K. PrangeA.J.Jr PostR.M. MuscettolaG. LiptonM.A. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.Am. J. Psychiatry19821391343810.1176/ajp.139.1.34 7055275
     [Google Scholar]
  33. ThaseM.E. KupferD.J. JarrettD.B. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine.J. Clin. Psychiatry19895010385388 2676995
     [Google Scholar]
  34. NgaerdeO. EdlundA.H. GormsenC.A. The effect of lithium carbonate in combination with tricyclic antidepressants in endogenous depression.Acta Psychiatr. Scand.19745023324210.1111/j.1600‑0447.1974.tb08212.x 4605253
     [Google Scholar]
  35. EbertD. JaspertA. MurataH. KaschkaW.P. Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients.Psychopharmacology1995118222322510.1007/BF02245845 7617812
     [Google Scholar]
  36. CappielloA. McDougleC.J. DelgadoP.L. Lithium and desipramine versus desipramine alone in the treatment of severe major depression.Int. Clin. Psychopharmacol.199813519119810.1097/00004850‑199809000‑00001 9817623
     [Google Scholar]
  37. Dé MontignyC. GrunbergF. MayerA. DeschenesJ.P. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders.Br. J. Psychiatry1981138325225610.1192/bjp.138.3.252 7272619
     [Google Scholar]
  38. HeningerG.R. CharneyD.S. SternbergD.E. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression.Arch. Gen. Psychiatry198340121335134210.1001/archpsyc.1983.01790110077013 6418110
     [Google Scholar]
  39. CournoyerG. de MontignyD. OuelletteJ. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. 14th Collegium Internationale Neuro-Psychopharmacologicum.June 19–23, 1984; Florence, Italy.1984
     [Google Scholar]
  40. SchöpfJ. BaumannP. LemarchandT. ReyM. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study.Pharmacopsychiatry198922518318710.1055/s‑2007‑1014603 2682692
     [Google Scholar]
  41. KatonaC.L.E. Abou-SalehM.T. HarrisonD.A. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.Br. J. Psychiatry19951661808610.1192/bjp.166.1.80 7894881
     [Google Scholar]
  42. BaumannP. NilR. SoucheA. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation.J. Clin. Psychopharmacol.199616430731410.1097/00004714‑199608000‑00006 8835706
     [Google Scholar]
  43. PareC.M.B. Al MousawiM. SandlerM. GloverV. Attempts to attenuate the ‘cheese effect’ combined drug therapy in depressive illness.J. Affect. Disord.19859213714110.1016/0165‑0327(85)90092‑8 2932486
     [Google Scholar]
  44. LaderM. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors.J. Clin. Psychiatry19834492024
     [Google Scholar]
  45. DevlinM.J. WalshB.T. Use of monoamine oxidase inhibitors in refractory depression. TasmanA. GoldfingerS.M. KaufmanC.A. American Psychiatric Press Review of Psychiatry.Washington, DCAmerican Psychiatric Press1990Vol. 97490
     [Google Scholar]
  46. JacobsenF.M. Possible augmentation of antidepressant response by buspirone.J. Clin. Psychiatry1991525217220 2033029
     [Google Scholar]
  47. BakishD. Fluoxetine potentiation by buspirone: Three case histories.Cancer J. Psychiatry1991361074975010.1177/070674379103601012 1790522
     [Google Scholar]
  48. JoffeR.T. SchullerD.R. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.J. Clin. Psychiatry1993547269271 8335654
     [Google Scholar]
  49. DimitriouE.C. DimitriouC.E. Buspirone augmentation of antidepressant therapy.J. Clin. Psychopharmacol.199818646546910.1097/00004714‑199812000‑00009 9864079
     [Google Scholar]
  50. BouwerC. SteinD.J. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression.S. Afr. Med. J.199787S4534537 9180827
     [Google Scholar]
  51. WeilburgJ.B. RosenbaumJ.F. BiedermanJ. SachsG.S. PollackM.H. KellyK. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report.J. Clin. Psychiatry19895012447449 2600061
     [Google Scholar]
  52. SethR. JenningsA.L. BindmanJ. PhillipsJ. BergmannK. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression.Br. J. Psychiatry1992161456256510.1192/bjp.161.4.562 1327396
     [Google Scholar]
  53. ZajeckaJ.M. JeffriesH. FawcettJ. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis.J. Clin. Psychiatry1995568338343 7635848
     [Google Scholar]
  54. NelsonJ.C. MazureC.M. BowersM.B.Jr JatlowP.I. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.Arch. Gen. Psychiatry199148430330710.1001/archpsyc.1991.01810280019002 2009031
     [Google Scholar]
  55. BoyerW.F. FeighnerJ.P. The combined use of fluoxetine and bupropion. 1995 annual meeting of the American Psychiatric Association. Miami, Fla.1995
     [Google Scholar]
  56. BodkinJ.A. LasserR.A. WinesJ.D.Jr GardnerD.M. BaldessariniR.J. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.J. Clin. Psychiatry199758413714510.4088/JCP.v58n0401 9164423
     [Google Scholar]
  57. SpierS.A. Use of bupropion with SRIs and venlafaxine.Depress. Anxiety199872737510.1002/(SICI)1520‑6394(1998)7:2<73:AID‑DA4>3.0.CO;2‑6 9614595
     [Google Scholar]
  58. MarshallR.D. JohannetC.M. CollinsP.Y. SmithH. KahnD.A. DouglasC.J. Bupropion and sertraline combination treatment in refractory depression.J. Psychopharmacol.19959328428610.1177/026988119500900313 22297770
     [Google Scholar]
  59. MarshallR.D. LiebowitzM.R. Paroxetine/bupropion combination treatment for refractory depression.J. Clin. Psychopharmacol.1996161808110.1097/00004714‑199602000‑00016 8834426
     [Google Scholar]
  60. PérezV. GilaberteI. FariesD. AlvarezE. ArtigasF. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.Lancet199734990651594159710.1016/S0140‑6736(96)08007‑5 9174562
     [Google Scholar]
  61. TomeM.B. IsaacM.T. HarteR. HollandC. Paroxetine and pindolol.Int. Clin. Psychopharmacol.1997122819010.1097/00004850‑199703000‑00003 9219043
     [Google Scholar]
  62. ZanardiR. ArtigasF. FranchiniL. How long should pindolol be associated with paroxetine to improve the antidepressant response?J. Clin. Psychopharmacol.199717644645010.1097/00004714‑199712000‑00002 9408806
     [Google Scholar]
  63. BordetR. ThomasP. DupuisB. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d’Expérimentation Psychopharmacologique.Am. J. Psychiatry1998155101346135110.1176/ajp.155.10.1346 9766765
     [Google Scholar]
  64. BessonA. HaddjeriN. DebonnelG. Effects of the Mirtazapine paroxetine combination on 5-HT neurotransmission in the rat forebrain.Soc. Neurosci.1998231225
     [Google Scholar]
  65. CappielloA. McDougleC.J. MalisonR.T. HeningerG.R. PriceL.H. Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study.Biol. Psychiatry1995381176576710.1016/0006‑3223(95)00367‑3 8580232
     [Google Scholar]
  66. DamJ. RydeL. SvejsøJ. LaugeN. LauritsenB. BechP. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression.Pharmacopsychiatry1998312485410.1055/s‑2007‑979298 9562208
     [Google Scholar]
  67. MaesM. LibbrechtI. van HunselF. CampensD. MeltzerH.Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.J. Clin. Psychopharmacol.199919217718210.1097/00004714‑199904000‑00014 10211920
     [Google Scholar]
  68. CarpenterL.L. JocicZ. HallJ.M. RasmussenS.A. PriceL.H. Mirtazapine augmentation in the treatment of refractory depression.J. Clin. Psychiatry1999601454910.4088/JCP.v60n0110 10074878
     [Google Scholar]
  69. OstroffR.B. NelsonJ.C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.J. Clin. Psychiatry199960425625910.4088/JCP.v60n0410 10221288
     [Google Scholar]
  70. McDougleC.J. FleischmannR.L. EppersonC.N. WasylinkS. LeckmanJ.F. PriceL.H. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: Three cases.J. Clin. Psychiatry19955611526528 7592506
     [Google Scholar]
  71. SaxenaS. WangD. BystritskyA. BaxterL.R.Jr Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.J. Clin. Psychiatry1996577303306 8666572
     [Google Scholar]
  72. SteinD.J. BouwerC. HawkridgeS. EmsleyR.A. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.J. Clin. Psychiatry199758311912210.4088/JCP.v58n0306 9108814
     [Google Scholar]
  73. SchneiderL.S. SmallG.W. HamiltonS.H. BystritskyA. NemeroffC.B. MeyersB.S. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial.Am. J. Geriatr. Psychiatry1997529710610.1097/00019442‑199721520‑00002 9106373
     [Google Scholar]
  74. HaoY. GeH. SunM. GaoY. Selecting an appropriate animal model of depression.Int. J. Mol. Sci.20192019482710.3390/ijms20194827 31569393
     [Google Scholar]
  75. RodgersR.J. DalviA. Anxiety, defence and the elevated plusmaze.Neurosci. Biobehav. Rev.1997216801810
     [Google Scholar]
  76. BiL.L. WangJ. LuoZ.Y. Enhanced excitability in the infralimbiccortex produces anxiety-like behaviors.Neuropharmacology201372148156
     [Google Scholar]
  77. KomadaM. TakaoK. MiyakawaT. Elevated plus maze for mice.J. Vis. Exp.2008221088 19229173
     [Google Scholar]
  78. ScheyerA. Safety in the shadows: Using the light/dark mazein anxiety research.2019Available from: https://conductscience.com/maze/safety-in-the-shadows-using-the-lightdarkmaze-in-anxiety-research
    [Google Scholar]
  79. BeeB.R. MohammadA. ShashiV. An insight through various models being used for assessment of depression and its management at primary level in current scenario.CNS Neurol. Disord. Drug Targets202322688489110.2174/1871527321666220516105907
     [Google Scholar]
  80. GouldT.D. DaoD.T. KovacsicsC.E. The open field test.Neuromethods20094212010.1007/978‑1‑60761‑303‑9_1
     [Google Scholar]
  81. SinghS. KumarP. Piperine in combination with quercetin halt 6-OHDA induced neurodegeneration in experimental rats: Biochemical and neurochemical evidences.Neurosci. Res.20181333847
     [Google Scholar]
  82. WillnerP. TowellA. SampsonD. SophokleousS. MuscatR. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant.Psychopharmacology198793335836410.1007/BF00187257 3124165
     [Google Scholar]
  83. LoweryO.H. RosenbroughN.J. FarrA.L. Protein measurement withFolin phenol reagent.J. Biochem.1951193265275
     [Google Scholar]
  84. AquibM. NajmiA. AkhtarM. Antidepressant effect of thymoquinone in animal models of depression.Drug Res.201465949049410.1055/s‑0034‑1389920 25207705
     [Google Scholar]
  85. SuF. WangF. ZhuR. LiH. Determination of 5-hydroxytryptamine, norepinephrine, dopamine and their metabolites in rat braintissue by LC-ESI-MS-MS.Chromatographia2009693-420721310.1365/s10337‑008‑0879‑9
     [Google Scholar]
  86. SinghS. KumarP. Neuroprotective potential of curcumin incombination with piperine against 6-hydroxy dopamine inducedmotor deficit and neurochemical alterations in rats.Inflammopharmacology2016911110.1007/s10787‑016‑0297‑9 27853890
     [Google Scholar]
  87. PatelB.A. ArundellM. ParkerK.H. YeomanM.S. O’HareD. Simpleand rapid determination of serotonin and catecholamines in biological tissue using high-performance liquid chromatography with electrochemical detection.J. Chromatogr. B.2005818269276
     [Google Scholar]
  88. LiX. Improved pyrogallol autoxidation method: A reliable and cheap superoxide-scavenging assay suitable for all antioxidants.J. Agric. Food Chem.201260256418642410.1021/jf204970r 22656066
     [Google Scholar]
  89. BorsiniF. Role of the serotonergic system in the forced swimming test.Neurosci. Biobehav. Rev.199519337739510.1016/0149‑7634(94)00050‑B 7566740
     [Google Scholar]
  90. MadrigalJ.L.M. MoroM.A. LizasoainI. LorenzoP. LezaJ.C. Stress-induced increase in extracellular sucrose space in rats is mediated by nitric oxide.Brain Res.20029381-2879110.1016/S0006‑8993(02)02467‑8 12031539
     [Google Scholar]
  91. BaekB.S. KwonH.J. LeeK.H. Regional difference of ROS generation, lipid peroxidaton, and antioxidant enzyme activity in rat brain and their dietary modulation.Arch. Pharm. Res.199922436136610.1007/BF02979058 10489874
     [Google Scholar]
/content/journals/cprr/10.2174/0126660822293380240516114111
Loading
Antidepressant Effect of Vincamine, Melatonin and their Combination in Experimental Rat Models of Depression
Curr Psyc Res Rev 21, 340 (2025); https://doi.org/10.2174/0126660822293380240516114111
/content/journals/cprr/10.2174/0126660822293380240516114111
/content/journals/cprr/10.2174/0126660822293380240516114111
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Depression; fluoxetine; melatonin; neurotransmitters; sucrose preference test; vincamine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test